Black Rock Inc. Immunovant, Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Immunovant, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 4,476,800 shares of IMVT stock, worth $118 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,476,800

Previous 4,530,716 1.19%

Holding current value

$118 Million

Previous $191 Million 24.22%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$30.27 - $43.79 $1.63 Million - $2.36 Million	-53,916 Reduced 1.19%	4,476,800 $145 Million
Q4 2023 Feb 13, 2024	BUY	$31.31 - $44.19 $12.5 Million - $17.6 Million	399,051 Added 9.66%	4,530,716 $191 Million
Q3 2023 Nov 13, 2023	SELL	$18.55 - $39.96 $1.29 Million - $2.78 Million	-69,649 Reduced 1.66%	4,131,665 $159 Million
Q2 2023 Aug 11, 2023	BUY	$14.2 - $23.75 $3.75 Million - $6.27 Million	264,133 Added 6.71%	4,201,314 $79.7 Million
Q1 2023 May 12, 2023	BUY	$15.27 - $19.72 $118,449 - $152,968	7,757 Added 0.2%	3,937,181 $61.1 Million

Q4 2022 Feb 13, 2023	BUY	$6.59 - $17.75 $2.79 Million - $7.5 Million	422,750 Added 12.06%	3,929,424 $69.7 Million
Q3 2022 Nov 14, 2022	SELL	$3.93 - $6.37 $489,819 - $793,931	-124,636 Reduced 3.43%	3,506,674 $19.6 Million
Q2 2022 Aug 12, 2022	BUY	$3.38 - $5.65 $937,760 - $1.57 Million	277,444 Added 8.27%	3,631,310 $14.2 Million
Q1 2022 May 12, 2022	BUY	$5.06 - $8.77 $146,056 - $253,146	28,865 Added 0.87%	3,353,866 $18.5 Million
Q4 2021 Feb 10, 2022	BUY	$7.33 - $9.32 $557,080 - $708,320	76,000 Added 2.34%	3,325,001 $28.3 Million
Q3 2021 Nov 09, 2021	BUY	$7.01 - $11.37 $1.02 Million - $1.66 Million	146,214 Added 4.71%	3,249,001 $28.2 Million
Q2 2021 Aug 11, 2021	BUY	$9.4 - $16.85 $29.2 Million - $52.3 Million	3,102,787 New	3,102,787 $32.8 Million

Others Institutions Holding IMVT

# of Institutions

238

Shares Held

62.9M

Call Options Held

1.46M

Put Options Held

546K

View Full List

About Immunovant, Inc.

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.41B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

More about IMVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account